Literature DB >> 30573629

NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.

Marcus Ruscetti1, Josef Leibold1, Matthew J Bott1, Myles Fennell1, Amanda Kulick2, Nelson R Salgado1, Chi-Chao Chen1, Yu-Jui Ho1, Francisco J Sanchez-Rivera1, Judith Feucht3, Timour Baslan1, Sha Tian1, Hsuan-An Chen1, Paul B Romesser1, John T Poirier2,4, Charles M Rudin2,4, Elisa de Stanchina2, Eusebio Manchado1, Charles J Sherr5,6, Scott W Lowe7,6.   

Abstract

Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence and activation of the immunomodulatory senescence-associated secretory phenotype (SASP). SASP components tumor necrosis factor-α and intercellular adhesion molecule-1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model. Therefore, molecularly targeted agents capable of inducing senescence can produce tumor control through non-cell autonomous mechanisms involving NK cell surveillance.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30573629      PMCID: PMC6711172          DOI: 10.1126/science.aas9090

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  33 in total

1.  The power and the promise of oncogene-induced senescence markers.

Authors:  Manuel Collado; Manuel Serrano
Journal:  Nat Rev Cancer       Date:  2006-06       Impact factor: 60.716

2.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Authors:  Wen Xue; Lars Zender; Cornelius Miething; Ross A Dickins; Eva Hernando; Valery Krizhanovsky; Carlos Cordon-Cardo; Scott W Lowe
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 4.  Tumor suppression by Ink4a-Arf: progress and puzzles.

Authors:  Scott W Lowe; Charles J Sherr
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

5.  A role for both RB and p53 in the regulation of human cellular senescence.

Authors:  J W Shay; O M Pereira-Smith; W E Wright
Journal:  Exp Cell Res       Date:  1991-09       Impact factor: 3.905

Review 6.  Critical pathways in cellular senescence and immortalization revealed by gene expression profiling.

Authors:  A L Fridman; M A Tainsky
Journal:  Oncogene       Date:  2008-08-18       Impact factor: 9.867

7.  Chemokine signaling via the CXCR2 receptor reinforces senescence.

Authors:  Juan C Acosta; Ana O'Loghlen; Ana Banito; Maria V Guijarro; Arnaud Augert; Selina Raguz; Marzia Fumagalli; Marco Da Costa; Celia Brown; Nikolay Popov; Yoshihiro Takatsu; Jonathan Melamed; Fabrizio d'Adda di Fagagna; David Bernard; Eva Hernando; Jesús Gil
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

8.  Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence.

Authors:  Masashi Narita; Sabrina Nũnez; Edith Heard; Masako Narita; Athena W Lin; Stephen A Hearn; David L Spector; Gregory J Hannon; Scott W Lowe
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

9.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Authors:  David W Fry; Patricia J Harvey; Paul R Keller; William L Elliott; Maryanne Meade; Erin Trachet; Mudher Albassam; XianXian Zheng; Wilbur R Leopold; Nancy K Pryer; Peter L Toogood
Journal:  Mol Cancer Ther       Date:  2004-11       Impact factor: 6.261

10.  Senescence of activated stellate cells limits liver fibrosis.

Authors:  Valery Krizhanovsky; Monica Yon; Ross A Dickins; Stephen Hearn; Janelle Simon; Cornelius Miething; Herman Yee; Lars Zender; Scott W Lowe
Journal:  Cell       Date:  2008-08-22       Impact factor: 41.582

View more
  101 in total

Review 1.  Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

Authors:  Erik S Knudsen; Steven C Pruitt; Pamela A Hershberger; Agnieszka K Witkiewicz; David W Goodrich
Journal:  Trends Cancer       Date:  2019-04-30

2.  Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors.

Authors:  Jessica L F Teh; Dan A Erkes; Phil F Cheng; Manoela Tiago; Nicole A Wilski; Conroy O Field; Inna Chervoneva; Mitch P Levesque; Xiaowei Xu; Reinhard Dummer; Andrew E Aplin
Journal:  Cancer Immunol Res       Date:  2020-07-13       Impact factor: 11.151

3.  Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer.

Authors:  Erik S Knudsen; Vishnu Kumarasamy; Sejin Chung; Amanda Ruiz; Paris Vail; Stephanie Tzetzo; Jin Wu; Ram Nambiar; Jared Sivinski; Shailender S Chauhan; Mukund Seshadri; Scott I Abrams; Jianmin Wang; Agnieszka K Witkiewicz
Journal:  Gut       Date:  2020-05-18       Impact factor: 23.059

Review 4.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

5.  The best Cas scenario.

Authors:  Peter Andrey Smith
Journal:  Nat Med       Date:  2018-05       Impact factor: 53.440

Review 6.  Cellular senescence in ageing: from mechanisms to therapeutic opportunities.

Authors:  Raffaella Di Micco; Valery Krizhanovsky; Darren Baker; Fabrizio d'Adda di Fagagna
Journal:  Nat Rev Mol Cell Biol       Date:  2020-12-16       Impact factor: 94.444

Review 7.  The cancer-natural killer cell immunity cycle.

Authors:  Nicholas D Huntington; Joseph Cursons; Jai Rautela
Journal:  Nat Rev Cancer       Date:  2020-06-24       Impact factor: 60.716

8.  Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.

Authors:  Laura Esteban-Burgos; Haiyun Wang; Patricia Nieto; Jie Zheng; Carmen Blanco-Aparicio; Carmen Varela; Gonzalo Gómez-López; Fernando Fernández-García; Manuel Sanclemente; Carmen Guerra; Matthias Drosten; Javier Galán; Eduardo Caleiras; Jorge Martínez-Torrecuadrada; Lluis Fajas; Sheng-Bin Peng; David Santamaría; Monica Musteanu; Mariano Barbacid
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-10       Impact factor: 11.205

9.  SIRT2 promotes murine melanoma progression through natural killer cell inhibition.

Authors:  Manchao Zhang; Scarlett Acklin; John Gillenwater; Wuying Du; Mousumi Patra; Hao Yu; Bo Xu; Jianhua Yu; Fen Xia
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

10.  Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.

Authors:  Johannes C Melms; Sreeram Vallabhaneni; Caitlin E Mills; Clarence Yapp; Jia-Yun Chen; Eugenio Morelli; Patricia Waszyk; Sushil Kumar; Derrick Deming; Nienke Moret; Steven Rodriguez; Kartik Subramanian; Meri Rogava; Adam N R Cartwright; Adrienne Luoma; Shaolin Mei; Titus J Brinker; David M Miller; Alexander Spektor; Dirk Schadendorf; Nicolo Riggi; Kai W Wucherpfennig; Peter K Sorger; Benjamin Izar
Journal:  Cancer Res       Date:  2019-12-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.